Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

about

Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase.Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun.Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.

P2860

Q33569519-00DEE8B3-935E-4FF2-BE5A-DA39C66623E6 Q40100857-DF107477-AC0D-4784-8BDD-860BACB37BAC Q44640499-A76E0B5A-A334-45BB-8C73-82846A9D13DA

P2860

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

Item

http://www.wikidata.org/entity/Q36598119

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

@ast

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

@en

type

Item

label

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

@ast

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

@en

prefLabel

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

@ast

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

@en

P1476

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

@en

P2093

Jason D Taylor

http://www.w3.org/2001/XMLSchema#string

Lisa L Osiecki

http://www.w3.org/2001/XMLSchema#string

Pramodini B Kale-Pradhan

http://www.w3.org/2001/XMLSchema#string

Sheila M Wilhelm

http://www.w3.org/2001/XMLSchema#string

P2860

Management of Crohn's disease in adults

Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

New concepts in the pathophysiology of inflammatory bowel disease.

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.

Medical options for treating Crohn's disease in adults: focus on antitumor necrosis factor-alpha chimeric monoclonal antibody.

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial.

P304

1804-1813

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1H038

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16985094

http://www.w3.org/2001/XMLSchema#string

P921

antibiotic

Crohn's disease

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

about

P2860

P2860

Novel therapies for Crohn's disease: focus on immunomodulators and antibiotics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921